• 6/26/2005
  • Austin, TX
  • press release
  • Austin Business Journal

Austin biopharmaceutical company Introgen Therapeutics Inc. received a patent that covers many of the features of its Advexin molecular therapy for cancer patients.

The patent is one of a family of patents that cover Advexin issued to the Board of Regents of The University of Texas System and exclusively licensed to Introgen.

“This important patent further expands Introgen’s formidable adenoviral p53 patent portfolio. This particular patent was specifically crafted to directly cover many of the special features of Introgen’s ADVEXIN product candidate, as well as to the host cells that are employed to produce the product,” says David Parker, Introgen’s vice president of Intellectual Property.

To date, Introgen has 30 issued patents and a number of pending patent applications in the U.S. and in foreign countries relating to its Advexin.

In 2003, Introgen’s investigational drug, Advexin, was granted “fast track” designation by the U.S. Food and Drug Administration as a treatment for head and neck cancer.

Introgen develops biopharmaceutical products for the treatment of cancer and other diseases. The company conducts research, development, manufacturing, clinical and regulatory activities at its Austin headquarters.

Print Friendly, PDF & Email